Utama › Kegagalan Jantung › Wisconsin › Milwaukee
Kajian klinikal Kegagalan Jantung di Milwaukee, WI
16 kajian untuk Kegagalan Jantung sedang mencari peserta di lokasi dalam dan sekitar Milwaukee (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
ELEVATE-HFpEF Clinical Study
Mengambil peserta
- Froedtert Hospital, Milwaukee
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Mengambil pesertaFasa 3
- ProHealth Care Research Institute and Cardiology Associates, Waukesha · 17 mi jauh
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Mengambil pesertaFasa 3
- Medical College of Wisconsin / Froedtert Hospital, Milwaukee
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Mengambil pesertaFasa 3
- Advocate Aurora Saint Lukes Medical Center, Milwaukee
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Mengambil pesertaFasa 3
- Milwaukee, WI Investigative Site 10061, Milwaukee
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Mengambil peserta
- Aurora St. Luke's Medical Center, Milwaukee
Peripheral Venous Pressure (PVP) Trial
Mengambil peserta
- Aurora St. Luke's Medical Center, Milwaukee
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Mengambil pesertaFasa 2
- Froedtert Hospital - Center for Advanced Care, Milwaukee
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Mengambil pesertaKajian pemerhatian
- Milwaukee, Milwaukee
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Mengambil pesertaKajian pemerhatian
- Medical College of Wisconsin, Inc (PI Address), Milwaukee
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Mengambil pesertaFasa 3
- Aurora St. Luke's Medi Ctr, Milwaukee
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Mengambil pesertaFasa 3
- Milwaukee, WI Investigative Site FIN-10428, Milwaukee
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Mengambil peserta
- Advocate Aurora St. Luke's, Milwaukee
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Mengambil peserta
- Aurora Medical Group, Milwaukee
CCM OPEN HF Registry
Mengambil pesertaKajian pemerhatian
- Advocate Aurora Health-St. Lukes, Milwaukee
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Mengambil peserta
- Advocate Aurora Research Institute, Milwaukee
Kajian Kegagalan Jantung di bandar lain
- New York City, NY51 kajian
- Boston, MA44 kajian
- Dallas, TX42 kajian
- Houston, TX36 kajian
- Cleveland, OH33 kajian
- Chicago, IL31 kajian
- Philadelphia, PA31 kajian
- San Francisco, CA29 kajian
- St. Louis, MO26 kajian
- Durham, NC26 kajian
- Kansas City, MO25 kajian
- Atlanta, GA25 kajian
Kajian lain di Milwaukee
- Kanser Payudara23 kajian
- Kanser Paru-paru Bukan Sel Kecil22 kajian
- Kanser (semua jenis)22 kajian
- Kanser Paru-paru21 kajian
- Mieloma Pelbagai21 kajian
- Kanser Prostat20 kajian
- Limfoma Folikular19 kajian
- Kanser Pankreas18 kajian
- Limfoma Bukan Hodgkin18 kajian
- Kanser Ovari17 kajian
- Leukemia Mieloid Akut17 kajian
- Limfoma Burkitt16 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.